Patents Assigned to Garnet BioTherapeutics, Inc.
-
Patent number: 10351826Abstract: Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and formulate pharmaceutical compositions.Type: GrantFiled: May 2, 2007Date of Patent: July 16, 2019Assignee: GARNET BIOTHERAPEUTICS, INC.Inventors: Tony W. Ho, Gene C. Kopen, William F. Righter, J. Lynn Rutkowski, Joseph Wagner
-
Patent number: 9051592Abstract: The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.Type: GrantFiled: March 12, 2013Date of Patent: June 9, 2015Assignee: Garnet Biotherapeutics, Inc.Inventors: Vanessa Ragaglia, Vandana Madanlal Sharma
-
Publication number: 20140099329Abstract: The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.Type: ApplicationFiled: August 19, 2013Publication date: April 10, 2014Applicant: Garnet BioTherapeutics, Inc.Inventors: GENE KOPEN, Joseph Wagner, Vanessa Ragaglia, Baron Heimbach, Richard S. Gore
-
Publication number: 20140073046Abstract: Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and formulate pharmaceutical compositions.Type: ApplicationFiled: March 11, 2013Publication date: March 13, 2014Applicant: Garnet BioTherapeutics, Inc.Inventor: Garnet Biotherapeutics, Inc.
-
Publication number: 20130190257Abstract: The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.Type: ApplicationFiled: January 18, 2013Publication date: July 25, 2013Applicant: Garnet BioTherapeutics, Inc.Inventor: Garnet BioTherapeutics, Inc.
-
Patent number: 8486696Abstract: Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and formulate pharmaceutical compositions.Type: GrantFiled: February 10, 2005Date of Patent: July 16, 2013Assignee: Garnet BioTherapeutics, Inc.Inventors: Tony W. Ho, Gene C. Kopen, William F. Righter, J. Lynn Rutkowski, Joseph Wagner
-
Patent number: 8354370Abstract: The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.Type: GrantFiled: June 16, 2008Date of Patent: January 15, 2013Assignee: Garnet BioTherapeutics, Inc.Inventors: Gene Kopen, Joseph Wagner, Vanessa Ragaglia, Baron Heimbach, Richard S. Gore
-
Publication number: 20120156192Abstract: The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.Type: ApplicationFiled: January 12, 2012Publication date: June 21, 2012Applicant: Garnet Biotherapeutics, Inc.Inventors: Gene KOPEN, Joseph WAGNER, Vanessa RAGAGLIA, Baron HEIMBACH, Richard S. GORE
-
Publication number: 20120148544Abstract: The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.Type: ApplicationFiled: January 12, 2012Publication date: June 14, 2012Applicant: Garnet Biotherapeutics, Inc.Inventors: Gene KOPEN, Joseph Wagner, Vanessa Ragaglia, Baron Heimbach, Richard S. Gore
-
Publication number: 20120121555Abstract: The invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.Type: ApplicationFiled: January 12, 2012Publication date: May 17, 2012Applicant: Garnet Biotherapeutics, Inc.Inventors: Gene KOPEN, Vanessa Ragaglia, Candace Brayfield
-
Publication number: 20120003188Abstract: The invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.Type: ApplicationFiled: May 27, 2011Publication date: January 5, 2012Applicant: Garnet Biotherapeutics, Inc.Inventors: Gene KOPEN, Vanessa RAGAGLIA, Candace BRAYFIELD